특허증
CERTIFICATE OF PATENT

특허
Patent Number
제 10-1739535 호

출원번호
Application Number
제 10-2016-0008903 호

출원일
Filing Date
2016년 01월 25일

등록일
Registration Date
2017년 05월 18일

발명의 명칭
Title of the Invention
태아의 염색체하수성을 검출하는 방법

특허권자
Patentee
지놀케어 주식회사(135811-******)
경기도 수원시 영통구 광교로 145, 비동 지하1층 (이의동, 차세대융합기술원)

발명자
Inventor
등록사항관에 기재

위의 발명은 「특허법」에 따라 특허등록원부에 등록되었음을 증명합니다.
This is to certify that, in accordance with the Patent Act, a patent for the invention has been registered at the Korean Intellectual Property Office.

2017년 05월 18일

특허청장
COMMISSIONER,
KOREAN INTELLECTUAL PROPERTY OFFICE

Korean Intellectual Property Office
특허증
CERTIFICATE OF PATENT

특허
Patent Number
제 10-1881098 호

출원번호
Application Number
제 10-2017-0060679 호

출원일
Filing Date
2017년 05월 16일

등록일
Registration Date
2018년 07월 17일

발명의 명칭
Title of the Invention
태아의 염색체이수성을 검출하는 방법

특허권자
Patentee
테라젠지놀케어 주식회사(135811-******)
경기도 수원시 영통구 광교로 145, 비동 지하1층 (이의동, 차세대융합기술원)

발명자
Inventor
등록사항란에 기재

위의 발명은 「특허법」에 따라 특허등록원부에 등록되었음을 증명합니다.
This is to certify that, in accordance with the Patent Act, a patent for the invention has been registered at the Korean Intellectual Property Office.

2018년 07월 17일

특허청장
COMMISSIONER,
KOREAN INTELLECTUAL PROPERTY OFFICE

성춘모
Korean Intellectual Property Office
특허증
CERTIFICATE OF PATENT

특허
Patent Number

제 10-2031841 호

출원번호
Application Number

제 10-2017-0178473 호

출원일
Filing Date

2017년 12월 22일

등록일
Registration Date

2019년 10월 07일

발명의 명칭 Title of the Invention
모체 시료 중 태아 분획을 결정하는 방법

특허권자 Patente

테라젠지놀케어 주식회사(135811-******)
경기도 수원시 영통구 창릉대로 260, 8층(이의동, 광교센트럴비즈타워)

발명자 Inventor

등록사항에 기재

위의 발명은 「특허법」에 따라 특허등록원부에 등록되었음을 증명합니다.
This is to certify that, in accordance with the Patent Act, a patent for the invention has been registered at the Korean Intellectual Property Office.

2019년 10월 07일

특허청장
COMMISSIONER,
KOREAN INTELLECTUAL PROPERTY OFFICE

박 원주

Korean Intellectual Property Office
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371

<table>
<thead>
<tr>
<th>International Application No.</th>
<th>International Filing Date</th>
<th>Priority Date Claimed</th>
</tr>
</thead>
</table>

Title of Invention
METHOD OF DETECTING FETAL CHROMOSOMAL ANEUPLOIDY

First Named Inventor
Sun Shin KIM

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)); NOTE: The express request under 35 U.S.C. 371(f) will not be effective unless the requirements under 35 U.S.C. 371(c)(1), (2), and (4) for payment of the basic national fee, copy of the International Application and English translation thereof (if required), and the oath or declaration of the inventor(s) have been received.

2. ☐ A copy of the International Application (35 U.S.C. 371(c)(2)) is attached hereto (not required if the International Application was previously communicated by the International Bureau or was filed in the United States Receiving Office (RO/US)).

   a. ☐ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(a)(4).

4. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4))
   a. ☐ is attached.
   b. ☐ was previously filed in the international phase under PCT Rule 4.17(iv).

Items 5 to 8 below concern amendments made in the international phase.

PCT Article 19 and 34 amendments

5. ☐ Amendments to the claims under PCT Article 19 are attached (not required if communicated by the International Bureau) (35 U.S.C. 371(c)(3)).

6. ☐ English translation of the PCT Article 19 amendment is attached (35 U.S.C. 371(c)(3)).

7. ☐ English translation of annexes (Article 19 and/or 34 amendments only) of the International Preliminary Examination Report is attached (35 U.S.C. 371(c)(5)).

Cancellation of amendments made in the international phase

8a. ☐ Do not enter the amendment made in the International phase under PCT Article 19.

8b. ☐ Do not enter the amendment made in the international phase under PCT Article 34.

NOTE: A proper amendment made in English under Article 19 or 34 will be entered in the U.S. national phase application absent a clear instruction from applicant not to enter the amendment(s).

The following items 9 to 17 concern a document(s) or information included.


10. ☐ A preliminary amendment.

11. ☐ An Application Data Sheet under 37 CFR 1.76.


13. ☐ A power of attorney and/or change of address letter.

14. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter; 3 and 37 CFR 1.821-1.825 (not required if sequence listing in text format was indicated on the PCT Request as part of the International Application and the sequence listing was published as part of the international application).

15. ☐ Assignment papers (cover sheet and document(s)) Name of Assignee:

16. ☐ 37 CFR 3.73(c) Statement (when there is an Assignee).

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.111 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Under the PAPERWORK REDUCTION ACT OF 1995, NO PERSONS ARE REQUIRED TO RESPOND TO A COLLECTION OF INFORMATION UNLESS IT DISPLAYS A VALID OMB CONTROL NUMBER.

a. ☐ A check in the amount of $______________ to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No: ________________, in the amount of $______________, to cover the above fees.

c. ☐ The Director is hereby authorized to charge additional fees which may be required, or credit any overpayment, to Deposit Account No. ________________ as follows:

   i. ☐ any required fee.

   ii. ☐ any required fee except for excess claims fees required under 37 CFR 1.492(d) and (e) and multiple dependent claim fee required under 37 CFR 1.492(f).

d. ☐ Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. The PTO-2038 should only be mailed or faxed to the USPTO. However, when paying the basic national fee, the PTO-2038 may NOT be faxed to the USPTO.

   ADVISORY: If filing by EFS-Web, do NOT attach the PTO-2038 form as a PDF along with your EFS-Web submission. Please be advised that this is not recommended and by doing so your credit card information may be displayed via PAIR. To protect your information, it is recommended to pay fees online by using the electronic payment method.

   NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.

---

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013, and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.

NOTE 1: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

NOTE 2: A U.S. national stage application may not claim priority to the international application of which it is the national phase. The filing date of a U.S. national stage application is the international filing date. See 35 U.S.C. 363.

---

Correspondence Address

☐ The address associated with Customer Number: ________________ OR ☐ Correspondence address below

Name

Address

City State Zip Code

Country Telephone

Email

---

Signature /Pattric J. Rawlins/ Date 19 JULY 2018

Name (Print/Type) Pattric J. Rawlins

Registration No. (Attorney/Agent) 47887

[Page 3 of 3]